Wangie Yu

Aug 14, 2024 | digitalcommons.library.tmc.edu | Wangie Yu |Yunyun Chen |Nagireddy Putluri |Abdullah Osman

BACKGROUND: Cisplatin (CDDP) is a mainstay treatment for advanced head and neck squamous cell carcinomas (HNSCC) despite a high frequency of innate and acquired resistance. We hypothesised that tumours acquire CDDP resistance through an enhanced reductive state dependent on metabolic rewiring.